Neoadjuvant Setting News Today

Experts discuss changes they foresee in the perioperative approach landscape for patients with NSCLC.

Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care

SEATTLE, Jan. 27, 2022 -- Atossa Therapeutics, Inc. , a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

4D pharma presents update on oncology program 4D pharma presents update on oncology program Enrollment progressing well for both expanded Part B of MRx0518 and Keytruda combination study, and pancreatic cancer study  Further analysis of biomarker data in ongoing MRx0518 neoadjuvant monotherapy study    Leeds, UK – February 3, 2021 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class ...